New opportunities in the therapy of steroid-specific dermatosis - combination of topical glucocorticosteroid with urinium

Cover Page


Cite item

Full Text

Abstract

External therapy with topical steroids is used for a long time. To date topical glucocorticosteroids (TGCS) are in the leading position in dermatology among all medicines for external therapy. TGCS as a powerful tool of pathogenic action can rapidly reduce or decrease inflammatory changes in the skin and eliminate subjective symptoms of dermatoses (itching, burning). their positive effect lead to the rehabilitation of working ability and daily living activity, positively affect the psychoemotional state and significantly improve the patient’s quality of life. Urea in dermatology has been used for a very long time, as it softens the skin, reduces its dryness and eliminates peeling. In recent decades interest in this compound has intensified after a formation of an idea about natural moisturizing factor (NMF) - a complex of substances (which includes urea) being a part of the intercellular matrix of the epidermis and capable of retaining the water in the epithelial layer of the skin necessary for its normal functioning. The article presents modern literature data on the reasoning of the inclusion of a combination of topical glucocorticosteroids with urea in a complex therapy of steroid-responsive dermatoses.

About the authors

N. N. Filimonkova

Ural Research Institute of Dermatovenereology and Immunopathology, Ministry of Health of Russia Federation

Author for correspondence.
Email: noemail@neicon.ru
Россия

M. S. Kolbina

City polyclinic № 46 of the Moscow City Health Department

Email: kolbinamary@mail.ru
Россия

References

  1. Boguniewicz M., Leung D. Y. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242 (1): 233-246.
  2. Lewin J., Friedlander S. F., et al. Atopic dermatitis and the stratum corneum, part 3: the immune system in atopic dermatitis. J Clin Aesthet Dermatol 2013; 6 (12): 37-44.
  3. Kungurov N. V., Filimonkova N. N. Tuzankina I. A., Berdnikov E. R. and others. The types of immunopathological processes in psoriatic disease. Ur Med Acad Science 2004; 2: 35-38. [Кунгуров Н. В., Филимонкова Н. Н., Тузанкина И. А., Бердникова Э. Р. и др. Типы иммунопатологических процессов при псориатической болезни. Вестник Ур Мед Акад Науки 2004; 2; 35-38.]
  4. Kubanova A. A., Kubanov A. A., Nicolas J. F., Pyuig L. et al. Immune mechanisms of psoriasis. New strategies of biological therapy. Vestn Dermatol Venereol 2010; 1: 35-47. [Кубанова А. А., Кубанов А. А., Николас Дж. Ф., Пьюиг Л. и др. Иммунные механизмы псориаза. Новые стратегии биологической терапии. Вестн дерматол венерол 2010; 1: 35-47.]
  5. Sergeev A. Y. Immunodermatologiya: immunological pathogenesis of inflammatory dermatoses main man [Text]. A. Y. Sergeev, A. V. Sentries, Y. Sergeev. Immunol Allergol Infectol 2003; 3: 16-19. [Сергеев А. Ю. Иммунодерматология: иммунологические основы патогенеза главных воспалительных дерматозов человека. А. Ю. Сергеев, А. В. Караулов, Ю. В. Сергеев. Иммунол, аллергол, инфектол 2003; 3: 16-19.]
  6. Volkova E. N., Lange D. A. Motherland Y. A., Tarasova M. V. Methylprednisolone atseponat in the treatment of chronic dermatoses: tactical error analysis using. Clin Dermatol Venereol 2010; 5: 84-88. [Волкова Е. Н., Ланге Д. А., Родина Ю. А., Тарасова М. В. Мтилпреднизолона ацепонат в комплексной терапии хронических дерматозов: анализ тактических ошибок применения. Клин дерматол венерол 2010; 5: 84-88.]
  7. Zaumseil R. P., Fuhrman H. et al. Methylprednisolone aceponate (Advantan) - an effective topical corticoid therapy with few side effects. Jabrbuch der Dermatologie 1992; 3: 247- 263.
  8. Scheinfeld N. S. A review of scientific and clinical data. Skinmed 2010; 8: 2: 102-106.
  9. Swanbeck G. A new treatment of ichthyosis and other hyperkeratotic conditions. Acta Derm Venerol 1968; 48: 123-127.
  10. Scheinfeld N. S. A review of scientific and clinical data. Skinmed 2010; 8: 2: 102-106.
  11. Horii Y., Tanida M., Shen J., Fujisaki Y., Fuyuki R., Hashimoto K., Niijima A., Nakashima T., Nagai K. Skin application of urea-containing cream affected cutaneous arterial sympathetic nerve activity, blood flow, and water evaporation. Skin Res Technol. 2011 Feb; 17 (1): 75- 81. doi: 10.1111/j.1600-0846.2010.00469.x.
  12. Grether-Beck S., Felsner I., Brenden H., Kohne Z., Majora M., Marini A., Jaenicke T., Rodriguez-Martin M., Trullas C., Hupe M., Elias P. M., Krutmann J. Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression. J Invest Dermatol. 2012 Jun; 132 (6): 1561-72. doi: 10.1038/jid.2012.42. Epub 2012 Mar 15.
  13. Feldmann R. J., Maibach H. I. Percutaneous penetration of hydrocortisone with urea. Arch Dermatol 1974 Jan; 109 (1): 58-9.
  14. Bien' K., Borkowski J. Initial appraisal of the value of urea in topical treatment. Przegl Dermatol 1974 May-Jun; 61 (3): 351-6.
  15. Stüttgen G. Results and consequences of long-term urea therapy for clinical practice. Hautarzt 1992; 43 Suppl 11: 9-12.
  16. Lodén M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol 2003; 4 (11): 771-88.
  17. Candi E., Schmidt R., Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Bio 2005; 6: 328-4.
  18. Loden M., Maibach HI Treatment of Dry Skin Syndrome. Springer-Verlag Berlin Heidelberg 2012
  19. Wellner K., Wohlrab W. Quantitative evaluation of urea in stratum corneum of human skin. Arch Dermatol Res 1993; 285: 239-40.
  20. Aberg K. M.,Man M. Q., Gallo R. L. et al. Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. J Invest Dermatol 2008; 128: 917-25.
  21. Klemenova I. A., Yesenin S. A. The evolution of the use of glucocorticoid drugs for local treatment in dermatological practice. Clin Dermatol Venereol 2011; 5: 46-50. [Клеменова И. А., Есенин С. А. Эволюция применения глюкокортикостероидных препаратов для местного лечения в дерматологической практике. Клин дерматол венерол 2011; 5: 46-50.]
  22. Filimonkova N. N., Bahlykova E. A. Topic glucocorticosteroids and 2% urea - a new means of external therapy of chronic dermatoses. Clin Dermatol Venereol 2015; 6: 30-35 [Филимонкова Н. Н., Бахлыкова Е. А. Топический глюкокортикостероид и 2% мочевина - новое средство наружной терапии хронических дерматозов. Клин дерматол венерол 2015; 6: 30-35.]
  23. Khardikova S. A. Application of a cream combined with the composition: Methylprednisolone atseponat 0.1% + 2% urea therapy in the face of dermatoses. Clin Dermatol Venereol 2016; 2: 74-80. [Хардикова С. А. Применение крема с комбинированным составом: метилпреднизолона ацепонат 0,1% + мочевина 2% в терапии дерматозов в области лица. Клин дерматол венерол 2016; 2: 74-80.]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Filimonkova N.N., Kolbina M.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies